Camelia Bhattacharyya, Amity University Kolkata
Potent diseases occur in both sexes, few are sex-specific; leiomyosarcoma (LMS) is one of them which affects mostly the female uterus, the limbs, and the retroperitoneum and accounts for about 11% of all adult soft tissue sarcomas (STS). While there are several types of LMS, the uterine LMS is the most common type and occurs in about 6 out of 10 lakhs of women and is the result for about 2% of all malignant uterine tumours. Recent research has shown that these LMS can be grouped into 2 major subdivisions, hLMS and oLMS.
The subgroups can be accurately identified through transcriptome analysis. The 2 different cohorts originate from different areas; hLMS is mostly carried by women and originates from the vascular smooth muscle cells and is thus both synthetic as well as contractile in character and can also be highly differentiated as identified through the genomic testing. oLMS, on the other hand, originates from fibroblasts.
These differentiations have also resulted in bringing to light the fact that MYOCD is an hLMS-specific driver and has strong expression. This proves that the MYOCD axis is essential for the survival of the hLMS. This again throws light on the fact that MYOCD inhibitors can act against hLMS can thus be used as therapy against these specific sarcomas.
Also read: mRNA vaccine: Efforts to dethrone coronavirus at the transcriptional level
Source: Darbo E, Pérot G, Darmusey L, Guellec SL, Leroy L, Gaston L, Desplat N, Thébault N, Merle C, Rochaix P, Valentin T, Ferron G, Chevreau C, Bui B, Stoeckle E, Vince DR, Méeus, Terrier P, Neumann SP, Colin F, Pinieux GD, Duffaud F, Coindre J-M, Blay J-Y, Chibon F. SRF-MYOCD axis is the targetable driver of a well differentiated aggressive subtype of leiomyosarcomas. bioRxiv preprint doi:http://10.1101/2020.10.23.352336
One thought on “Are researchers finding therapies to treat the types of sarcomas?”